Ceritinib is a small molecule ALK TKI that has demonstrated efficacy in ALK-positive tumors including ALCL, inflammatory myofibroblastic tumor, neuroblastoma, and rhabdomyosarcoma; in ALK+ ALCL, the most commonly reported complication was elevated transaminases (103). The gene discussed is ALK; the disease is neuroblastoma.